The PDWP aims to support research and education to improve the availability, safety, and efficacy of HSCT and other cellular therapeutics for children and adolescents; to engage and promote active co-operation with all EBMT working parties treating children and adolescents in an effort to meet the total needs of the full spectrum of paediatric HSCT patients; to initiate and perform prospective, collaborative, GCP-conform studies for malignant and non malignant paediatric diseases; to develop further the close collaboration with experts from the Leukaemia/Chemotherapy national frontline studies in order to define the optimal timing of HSCT and incorporate transplant recommendations into the disease-specific protocols; to implement the new regulations on paediatric medicines from the EMEA; to offer physicians and nursing staff from small or new centres practical training and fellowships in experienced transplantation units through a European Collaborative Paediatric HSCT network; to further develop established Paediatric Standards within the Accreditation Process through JACIE to guarantee and maintain a high quality of patient care and experience.
Subcommittees & Members
PDWP Subcommittee Goals and Action Plans
PDWP Publications List
Guidelines, Consensus Statements, and Position Papers
Proposing the study idea and submitting and selecting the study protocol for EBMT Working Party studies.